CC
LEGN icon

Casdin Capital’s Legend Biotech LEGN Stock Holding History

Casdin Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-215,000
Closed -$4.67M – 44
2025
Q4 		$4.67M Buy
+215,000
New +$6.16M 0.29% 30
2020
Q4 		– Sell
-139,661
Closed -$4.31M – 54
2020
Q3 		$4.31M Buy
139,661
+4,661
+3% +$157K 0.19% 43
2020
Q2 		$5.75M Buy
+135,000
New +$5.27M 0.34% 38

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Casdin Capital's LEGN Position: Q1 2026 in Review

Casdin Capital sold out of Legend Biotech (LEGN) in Q1 2026, closing a stake of 215,000 shares — an estimated $4.67M sold.

Casdin Capital first reported a position in LEGN in Q2 2020 and held it in 3 quarters. The position peaked at $5.75M in Q2 2020. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Casdin Capital reported no remaining Legend Biotech position as of Q1 2026 after selling out during the quarter.
  • Casdin Capital sold 215,000 Legend Biotech shares in Q1 2026, an estimated $4.67M.
  • Casdin Capital first reported a position in Legend Biotech in Q2 2020 and held it in 3 quarters.
  • Casdin Capital's Legend Biotech position peaked at $5.75M in Q2 2020.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.